Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 24, 2003. The report details specific corporate actions regarding share re-purchases and changes in directors' interests in ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific share transaction:
- Shares Repurchased: 837,000 ordinary shares.
- Price per Share: 1193.8224p.
- Purpose: Purchased for cancellation.
Material Changes
The filing reports the following material changes and transactions:
- Share Re-purchase: Execution of a buyback program authorized by shareholders at the Annual General Meeting on May 20, 2002.
- Employee Benefit Trust Transfers:
- 11,023 ordinary shares transferred from the SmithKline Beecham Employee Benefit Trust to participants of the 1991 Share Option Plan.
- 485 ordinary shares transferred from the Trust to a participant in the UK Bonus Investment Plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items beyond the routine disclosure of share transactions and director interests.
Investor Verification Checklist
- Verify the total number of shares remaining in the authorized re-purchase program following the cancellation of 837,000 shares.
- Confirm the impact of the share cancellation on the company's total share count and earnings per share.
- Review the full Annual Report (Form 20-F) for comprehensive financial performance data not included in this 6-K.